“Novo Nordisk heard loud and clear the impact to the 15,000 Australians living with diabetes who depended on FIASP, if FIASP was no longer available on the PBS. We are pleased that patients can continue accessing this treatment on the PBS,” said Cem Ozenc, corporate vice president and general manager of Novo Nordisk Oceania. …
Patients win reprieve with Novo Nordisk listing a new form of insulin aspart
September 17, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
Georgia Forrest
New Stories
-
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News -
Tiny fragments of RNA, a giant opportunity for autoimmune disease treatment
February 10, 2026 - - Australian Biotech -
BCEC partners with Life Sciences Queensland to launch bursary for next-gen bio innovation leaders
February 10, 2026 - - Australian Biotech -
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 - - Australian Biotech -
Algorae expands commercial footprint with new licensing deal
February 10, 2026 - - Australian Biotech